These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30114224

  • 1. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T.
    PLoS One; 2018; 13(8):e0201956. PubMed ID: 30114224
    [Abstract] [Full Text] [Related]

  • 2. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T.
    BMC Pediatr; 2019 Oct 13; 19(1):351. PubMed ID: 31607268
    [Abstract] [Full Text] [Related]

  • 3. Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn's disease?
    Herman R, Sładek M, Pieczarkowski S, Dumnicka P, Fyderek K.
    Folia Med Cracov; 2017 Oct 13; 57(2):63-71. PubMed ID: 29121038
    [Abstract] [Full Text] [Related]

  • 4. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
    Kierkuś J, Iwańczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Łazowska I, Maślana J, Toporowska-Kowalska E, Czaja-Bulsa G, Mierzwa G, Korczowski B, Czkwianianc E, Żabka A, Szymańska E, Krzesiek E, Więcek S, Sładek M.
    J Pediatr Gastroenterol Nutr; 2015 May 13; 60(5):580-5. PubMed ID: 25564804
    [Abstract] [Full Text] [Related]

  • 5. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease.
    Marshanski T, Fanous E, Tal N, Perets TT, Matar M, Weintraub Y, Shamir R, Shouval DS.
    J Pediatr Gastroenterol Nutr; 2024 Sep 13; 79(3):564-572. PubMed ID: 38979682
    [Abstract] [Full Text] [Related]

  • 6. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
    Chanchlani N, Mortier K, Williams LJ, Muhammed R, Auth MKH, Cosgrove M, Fagbemi A, Fell J, Chong S, Zamvar V, Hyer W, Bisset WM, Morris MA, Rodrigues A, Mitton SG, Bunn S, Beattie RM, Willmott A, Wilson DC, Russell RK.
    J Pediatr Gastroenterol Nutr; 2018 Oct 13; 67(4):513-519. PubMed ID: 29697550
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
    Colman RJ, Vuijk SA, Mathôt RAA, Van Limbergen J, Jongsma MME, Schreurs MWJ, Minar P, de Ridder L, D'Haens GRAM.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1678-1685. PubMed ID: 38167922
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy and safety of infliximab in the treatment of pediatirc Crohn's disease].
    Xu X, Xiao Y, Yu Y, Li J, Huang YQ, Cao W, Hu H, Zhang T, Xu CD, Wang XQ.
    Zhonghua Er Ke Za Zhi; 2021 Jul 02; 59(7):557-562. PubMed ID: 34405637
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM, Lachaux A, Cézard JP, Morali A, Maurage C, Giniès JL, Viola S, Goulet O, Lamireau T, Scaillon M, Breton A, Sarles J, Groupe Francophone d'Hépatologie, Gastroentérologie et Nutrition Pédiatrique.
    Inflamm Bowel Dis; 2009 Mar 02; 15(3):388-94. PubMed ID: 19023899
    [Abstract] [Full Text] [Related]

  • 13. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA, Cohen BL, Colombel JF, Sands BE, Mayer L, Agarwal S.
    J Crohns Colitis; 2015 Mar 02; 9(3):266-75. PubMed ID: 25540149
    [Abstract] [Full Text] [Related]

  • 14. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R, Lee D, Leonard MB, Thayu M, Denson LA, Chuang E, Herskovitz R, Kerbowski T, Baldassano RN.
    Inflamm Bowel Dis; 2016 Jun 02; 22(6):1370-7. PubMed ID: 27057683
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
    Ling J, Buurman D, Ravikumara M, Mews C, Thacker K, Grover Z.
    Dig Dis Sci; 2018 Apr 02; 63(4):1003-1010. PubMed ID: 29480415
    [Abstract] [Full Text] [Related]

  • 19. Infliximab serum concentrations and disease activity in perianal fistulizing Crohn's disease: a cross-sectional study.
    Miranda EF, Nones RB, Baraúna FB, de Nardi Marçal G, Olandoski M, de Moraes TP, Kotze PG.
    Tech Coloproctol; 2024 Jul 20; 28(1):86. PubMed ID: 39031218
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.